DUB targets explored
In the DUB field
Commercializing expert research into
Dubs and Ubiquitin pathway
Mission Therapeutics’ strategy is to create value by advancing its pipeline programs through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Selected programmes may be advanced in partnership with other pharmaceutical companies.
- Mission Therapeutics Appoints Dr Bobby Soni to its Board of Directors8th March 2018
- Mission Therapeutics Strengthens Senior Management Team with Appointment of Dr Paul Thompson, Vice President, Clinical Development1st March 2018
- Mission Therapeutics’ Highlights Positive Parkinson’s Disease USP30 Target and Inhibitor Data at the Society for Neuroscience 2017 Annual Meeting16th November 2017